Virus-mediated gene delivery shows promise for the treatment of chronic pain. However, viral vectors have cytotoxicity. To avoid toxicities and limitations of virus-mediated gene delivery, we developed a novel nonviral hybrid vector: HIV-1 Tat peptide sequence modified with histidine and cysteine residues combined with a cationic lipid. The vector has high transfection efficiency with little cytotoxicity in cancer cell lines including HSC-3 (human tongue squamous cell carcinoma) and exhibits differential expression in HSC-3 (;45-fold) relative to HGF-1 (human gingival fibroblasts) cells. We used the nonviral vector to transfect cancer with OPRM1, the m-opioid receptor gene, as a novel method for treating cancer-induced pain. After HSC-3 cells were transfected with OPRM1, a cancer mouse model was created by inoculating the transfected HSC-3 cells into the hind paw or tongue of athymic mice to determine the analgesic potential of OPRM1 transfection. Mice with HSC-3 tumors expressing OPRM1 demonstrated significant antinociception compared with control mice. The effect was reversible with local naloxone administration. We quantified b-endorphin secretion from HSC-3 cells and showed that HSC-3 cells transfected with OPRM1 secreted significantly more b-endorphin than control HSC-3 cells. These findings indicate that nonviral delivery of the OPRM1 gene targeted to the cancer microenvironment has an analgesic effect in a preclinical cancer model, and nonviral gene delivery is a potential treatment for cancer pain.
Introduction
Patients with oral cancer often have severe function-induced pain when they eat, drink, or speak. Quality of life is severely degraded in these patients. 1, 14, 21 The intensity and prevalence of pain is generally higher in patients with oral cancer than in patients with other types of cancer. 32, 48 Oral cancer pain escalates with disease progression. Although opioids are initially effective for oral cancer pain, patients develop tolerance and require ever larger narcotic doses. Unfortunately, high-dose opioids have limited efficacy when administered over an extended duration, and off-target effects are severe.
Gene therapy holds potential for treating cancer pain along with other types of chronic pain; a single injection could produce a long-term effect 56 and target molecules involved in the pathophysiology of pain. 52 Several potential gene targets for cancer pain therapy are already known. EDNRB, the gene for the endothelin B (ET B ) receptor, is silenced in human oral squamous cell carcinoma (SCC) tissues, and adenovirus-mediated reexpression of EDNRB produces antinociception in a mouse cancer model. 50 Similarly, we show that OPRM1, the m-opioid receptor (MOR) gene, is hypermethylated and transcriptionally silenced in human oral SCC (HSC). We also demonstrated that adenovirus-mediated re-expression of OPRM1 produces antinociception in a mouse cancer model. 49 Although our adenovirus-mediated gene transduction approach showed promising analgesic effects in a preclinical model, its translational potential is limited. 50 Viral transduction induces a strong immune response, and the duration of gene transduction is limited. 22 Toxicity with viral vectors remains a concern; study subjects have died during clinical trials of adenovirus vectors 10 and adeno-associated virus vectors. 7 To preclude complications related to viral vectors, several studies have used intrathecal injection of naked plasmid, 23, 34 liposomalcomplexed DNA, 46, 47 or polymer-complexed DNA. 1, 33 A clinical trial of intrathecally injected naked plasmid encoding interleukin 10 (IL-10) in patients with chronic neuropathic pain has also been proposed. 30 Nonviral vectors generate a smaller immune response compared with viral vectors. 20, 44 Moreover, nonviral transfection facilitates delivery of genes that are too large to be carried by viruses. The in vivo efficiency of currently available nonviral vectors is too low for therapeutic purposes. 38 To avoid limitations associated with available nonviral vectors, we created a novel nonviral hybrid vector composed of a modified HIV-1 Tat peptide (mTat) and a cell-permeable peptide combined with a cationic lipid, a FuGENE HD (FH) transfection reagent. 55 Our nonviral vector has excellent transfection efficiency with low cytotoxicity across a range of cell lines, including different types of cancer cells; transfection with our nonviral vector leads to high and long-term transgene expression (;7 months) after intramuscular injection of the vector in vivo. 54 Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
We hypothesize that nonviral gene transfection can stably reexpress silenced genes and treat cancer-induced pain as effectively as viral transduction. Here, we demonstrate the effects of OPRM1 transfection of cancer cells using a nonviral vector in 2 (paw and tongue) mouse cancer pain models. We show analgesia in response to OPRM1 transfection in both models.
Methods

Cell culture
Human oral SCC, HSC-3, and human gingival fibroblasts, HGF-1, were cultured in Dulbecco Modification of Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Life Technologies, Grand Island, NY) and 1% penicillin G (Life Technologies) with streptomycin sulfate. All cells were cultured at 37˚C in a humidified atmosphere with 5% CO 2 . This same medium was used for transfection.
Plasmid DNAs
Plasmid DNA encoding for luciferase (gWIZ luciferase) and the green fluorescent protein (GFP) (gWIZ GFP) under the control of the cytomegalovirus promoter/enhancer obtained from Genlantis (San Diego, CA), and plasmid DNA encoding OPRM1-GFP (OriGene, Rockville, MD) were used. Vectors were propagated in competent Escherichia coli DH5a cells (Life Technologies). Ultrapure endotoxin-free plasmid DNA was prepared using the QIAfilter kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Each plasmid DNA was diluted in sterile water to a final concentration of 1 mg/mL DNA.
Nonviral vector
The HIV-1 Tat (RKKRRQRRRR) covalently fused with 10 histidine and 2 cysteine residues (C-5H-Tat-5H-C), mTat was obtained from Biomatik Corporation (Cambridge, ON, Canada). To prepare mTat/DNA complexes, the peptide solution (1 mM) and plasmid DNA encoding the gene for either GFP or OPRM1-GFP (2 mg/well each) were mixed in 5% glucose solution to a final volume of 60 mL/well. The solution was quickly mixed for 5 seconds. After the mixture was incubated at room temperature for 30 minutes, the cap of the sample tube was opened to expose the solution to air. The sample was shaken vigorously for 90 minutes. The cap was opened intermittently to allow for air replenishment. Plasmid DNA (2 mg/well) encoding the gene for either GFP alone as a control or OPRM1-GFP was added to FH (Roche, Indianapolis, IN), and then incubated at room temperature for 15 minutes. Sixty mL complexes (containing 2 mg DNA and FH) were added into a 6-well plate. Two vector/DNA groups were used as follows: group 1, mTat/FH/GFP, and group 2, mTat/FH/OPRM1-GFP.
In vitro plasmid DNA transfection for luciferase expression
For luciferase expression, cells were plated in a 96-well plate at a density of 2 3 10 5 cells/mL (100 mL/well), cultivated in the appropriate growth medium with 10% FBS. One hundred mL of media with 10% FBS was added to each well. After 24 hours in culture, the old culture medium was aspirated and 100 mL fresh media with 10% FBS was added to each well. The vector/DNA (luciferase plasmid) complexes were then added to each well and incubated. The cells were cultured for 48 hours at 37˚C in 5% (vol/ vol) CO 2 after transfection. All transfection assays were performed in quadruplicate simultaneously. Also, we tested the cells treated with plasmid only as the controls.
For GFP or OPRM1-GFP expression, cells were plated in a 6-well plate at a density of 2 3 10 5 cells/mL (1 mL/well), cultivated in the appropriate growth medium with 10% FBS. One ml of media with 10% FBS was added to each well. After 24 hours in culture, 1 mL fresh media with 10% FBS was added to the cells. Sixty mL of the vector/DNA (GFP or OPRM1-GFP plasmid) complexes were then added to each well and incubated with the cells for 48 hours at 37˚C in 5% (vol/vol) CO 2 after transfection. Transfection assays were performed in quadruplicate simultaneously. To employ stable transfection for ex vivo gene delivery in mice, the medium was changed to selection medium containing 0.8 mg/mL of G418 sulfate (Gemini Bio-Products, West Sacramento, CA). After the cells were cultured for 1 to 2 weeks, media was changed to a lower concentration of selection media containing 0.4 mg/mL of G418 sulfate. The cells were cultured for 40 days in the selection medium.
Detection of transgene expression
Transgene expression was detected at a standardized representative time point of 48 hours after transfection. Luciferase expression level was measured with Bright-Glo Luciferase Assay System (Promega, Madison, WI) using a multidetection microplate reader, SpectraMax M5 (Molecular Devices, LLC, Sunnyvale, CA). Relative light units (RLUs) were recorded in duplicates with 10-s integration. This detection system is designed to measure directly the expression level using 96-well plates. The use of relative light units/well as the unit of measure allowed for accurate detection of expression levels and is considered a well-accepted method in the field.
Cell viability evaluation
Cell viability of HSC-3 cells after transfection with the transfection reagents was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), assay. Human oral SCC-3 cells (1 3 10 6 /mL) in 100 mL of DMEM supplemented with 10% FBS were seeded in 96-well plates and incubated overnight. Then HSC-3 cells were transfected with mTat/FH/GFP or mTat/FH/ OPRM1-GFP complex and incubated for 24 or 48 hours. The 5 mg/mL MTT reagent in 13 PBS (10 mL/well) was added to the plates and incubated for 4 hours. After incubation, the medium was aspirated and dimethyl sulfoxide (100 mL/well) was added to stop the reaction. The optical density was quantified in a multidetection microplate reader, SpectraMax M5, at 570 nm wavelength. The percentage of cell viability was calculated by comparing the appropriate optical density to the control cells that were not transfected.
Zeta potential
Zeta potentials of HGF-1 and HSC-3 cells were measured at 25˚C by a Zetasizer Nano ZS90 (Malvern Instruments Ltd, Malvern, Worcestershire, United Kingdom). This instrument is equipped with a red laser of wavelength 630 nm and measures the electrophoretic mobility of the particles using phase analysis of scattered light in an experimental set up similar to Laser Doppler Velocimetry (M3PALS technique, Malvern Instruments Ltd). Zeta potential was derived from the electrophoretic mobility using the Smoluchowski model since the measurements were performed in aqueous solutions of moderate ionic strength (ie, electrical double layer thickness ,, the particle size). Each sample was observed with 20 repeated measurements across 3 trials.
Quantitative real-time PCR with reverse transcription
For caveolin mRNA expression, the total RNA in the harvested HSC-3 and HGF-1 cells was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. The cells were homogenized in a lysis buffer. The lysis buffer containing the homogenate was centrifuged for 1 minute at 13,000g at 4˚C. The supernatant was applied to RNeasy column, rinsed, and eluted. RNAs were measured by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE), and cDNA was synthesized using a total of 1 mg RNA using QuantiTect Quantiscript reverse-transcriptase and RT Primer Mix (Qiagen), according to the manufacturer's protocol. Real-time PCR was performed using Opticon Monitor 3 (Bio-Rad, Hercules, CA) with Rotor-Gene SYBR Green (Qiagen), according to standard protocols. The sequences of caveolin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene-specific primers are as follows: caveolin forward: 59-AAGACCTGCCTAATGGTTCTGC-39; reverse: 59-CTCGTACACAATGGAGCAATGAT-39; GAPDH forward: 59-ACACCCACTCCTCCACCTTT-39; GAPDH reverse: 59-TAGCCAAATTCGTTGTCATACC-39. Standard curves were generated for each gene, and the amplification was found to be 90%-100% efficient. The relative quantification of gene expression was determined by the comparison of threshold values. All the results were normalized to GAPDH gene. The results presented are the average of 4 replicate experiments. All the graphic data for mRNA expression are presented as the fold expression relative to the reference control cells.
For OPRM1 mRNA expression, the total RNA in the harvested HSC-3 cells was isolated with RNeasy Mini Kit, according to the manufacturer's instructions. The transfected HSC-3 cells were first homogenized for 30 seconds in a lysis buffer. The lysis buffer containing the homogenate was centrifuged for 1 minute at 13,000g at 4˚C. The supernatant was applied to RNeasy column, rinsed and eluted. RNA concentration was measured by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies) and treated with DNase I. mRNA was reverse transcribed with random hexamers. An 8-mL cDNA aliquot was amplified in 25 mL of 23 TaqMan universal PCR master mix and 2.5 mL of 203 TaqMan primer and probe mix (Applied Biosystems, Carlsbad, CA) under the following PCR conditions: 2 minutes at 50˚C, 10 minutes at 95˚C, 50 cycles of 95˚C for 15 seconds, and 60˚C for 1 minute. The TaqMan gene expression assay for OPRM1 (Hs01053957_ml, Applied Biosystems) was used as it does not detect residual genomic DNA. Human b-glucuronidase (GUSB, 4,326,320E, Applied Biosystems) was used as the endogenous control. Threshold analysis was performed using the software supplied with the Opticon Monitor 3 (Bio-Rad). Each sample was measured in quadruplicate. Relative OPRM1 transcript levels were determined using the 2 2DDCt method with GUSB as the internal control.
Fluorescence microscope
To observe transgene GPF protein expression, 48 hours after transfection, the medium was removed, and the cells were rinsed twice with PBS. Images of GFP expression were captured using a fluorescence microscope, Axiovert 200 and AxioCan digital camera both from Carl Zeiss (Thornwood, NY), and processed with SPOT software version 4.6 (Diagnostic Instruments Inc, Sterling Heights, MI). Transfection efficiency was measured by the following steps: (1) randomly counting 5 fluorescence (F) field views and 5 black (B) field views for each well, and (2) calculating the transfection efficiency rate (%), the mean cell numbers of F were divided by the mean cell numbers of B and multiplied by 100.
Enzyme-linked immunosorbent assay
The MOR was measured in HGF-1 and HSC-3 cells transfected with GFP plasmid or OPRM1 plasmid using an enzyme-linked immunosorbent assay (ELISA; MyBioSource Inc, San Diego, CA). Cells were seeded at a density of 3 3 10 5 cells/mL in a 10-cm culture plate. After 24 hours of incubation, medium was removed and cells were rinsed with ice-cold PBS, then cells were scraped from the plate and collected. Enzyme-linked immunosorbent assay was performed according to manufacturer's instructions. Samples were run in quadruplicate and measured using a spectrophotometer at the recommended wavelength.
The opioid peptides b-endorphin, met-enkephalin, and leuenkepalin were quantified in the supernatant of OPRM1-expressing HGF-1 and HSC-3 cells with or without OPRM1 antagonist D-PheCys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP; Sigma-Aldrich, St. Louis, MO) using an ELISA (MD Bioproducts, St. Paul, MN). Four sample groups were prepared as follows: (1) 
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, and 10 212 M) for 1 hour at 37˚C. Cells were seeded at a density of 2 3 10 5 cells/mL (500 mL/well) and were grown to 70% to 80% confluence in 24-well plates, then incubated for 24 hours in 1-mL fresh DMEM with 10% FBS and supplements. Cell supernatant was collected, and 10 mL Halt protease inhibitor (Thermo Scientific, Rockford, IL) was added. Samples were transferred to the b-endorphin ELISA plate, and ELISA was performed according to manufacturer's instructions. Samples were run in quadruplicate and measured using a spectrophotometer at the recommended wavelength. The minimum detectable dose of b-endorphin, met-enkephalin, or leu-enkephalin ELISA kit was 10, 1, and 100 pg/mL, respectively.
Squamous cell carcinoma mouse model
The cancer pain mouse model was produced as previously described. 39 Experiments were performed on adult female BALB/ c, athymic, immunocompromised mice weighing 16 to 20 g at the time of SCC inoculation. The mice were housed in a temperaturecontrolled room on a 12:12 hours light cycle (0700-1900 hours light), with unrestricted access to food and water. All the procedures were approved by the New York University Committee on Animal Research. Researchers were trained under the Animal Welfare Assurance Program. Twenty mice were divided into 2 inoculation groups and inoculated with the respective cell types: (1) HSC-3 expressing GFP and (2) HSC-3 expressing OPRM1. Cells (10 7 ) from each group, after 40-day stable transfection, were suspended in Matrigel (Becton Dickinson & Co, Franklin Lakes, NJ) to a total volume of 50 mL and inoculated into the plantar surface of the right hind paw. Inhalational isoflurane at 2% to 5% was used for anesthesia to inoculate.
Paw volume measurement and cellular proliferation for squamous cell carcinoma paw model
Paw volume measurements were performed using a plethysmometer (IITC Life Sciences, Woodland Hills, CA). The paw was inserted into a water cell of which pressure is changed due to the immersion. The volume change was calibrated in milliliters and shown on an electronic monitor. The measurements were accurate by 1 mL. Triplicate measurements were taken for each mouse. Paw volume measurements were made at 0, 13, and 17 days relative to inoculation of HSC-3 cells. Each mouse was used as its own control, and relative changes in paw volume were calculated based on day 0 baseline. Cellular proliferation was also measured in the cancers using Ki67, a nuclear protein used to evaluate proliferation. Cancer sections from animals in the OPRM1 and GFP groups were stained for Ki67 (rabbit antiKi67, 1:400; Abcam, Cambridge, MA). After incubation in primary antibody, sections were rinsed in PBS 3 times for 10 minutes each and then incubated in the FITC Fluorescein IsothiocyanateAffiniPure goat anti-rabbit secondary antibody (1:400; Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 hour at room temperature. The number of positive cells was counted in 3 randomly selected sections from 3 mice per treatment group.
Mechanical allodynia measurement in the paw cancer mouse model
Paw withdrawal testing was performed as described previously. 39 Testing was performed by an observer blinded to the experimental groups. Mice were placed in a plastic cage with wire mesh floor, which allowed access to the paws. One hour was allowed for acclimation before testing. The probe was applied to the mid-plantar right hind paw. Paw withdrawal threshold was determined in response to pressure from an electronic von Frey anesthesiometer (2390 series; IITC Life Sciences). The amount of pressure (g) needed to produce a paw withdrawal response was measured 6 times on each paw separated by 3 minutes intervals to allow resolution of the previous stimulus. The results of the 6 values were averaged for each paw for that day. Behavioral measurements were performed on postinoculation days (PIDs) 13 and 17, when tumor growth was present in all animals.
Thermal hyperalgesia measurement in the paw cancer mouse model
Thermal hyperalgesia of the hind paw was quantified according to the Hargreaves method. 19 Mice were acclimated to the test room and chamber for 30 minutes twice a week for 2 weeks. Mice were then acclimated in the Plantar Test Apparatus for 30 minutes before actual testing. The device consisted of a glass surface on which the mice were placed individually in Plexiglass cubicles. The glass surface temperature was maintained at 30˚C. The thermal nociceptive stimulus originating from a focused projection bulb was manually manipulated to permit the stimulus to be delivered separately to the hind paw of each test animal. This stimulus was positioned under the right footpad of each mouse. The elapsed time required for a paw withdrawal response was measured automatically and considered an index of the heat nociceptive threshold. Paw withdrawal to heat was calculated as a mean of 6 measurements, performed at 3-minute intervals. An automatic 20-second cutoff was used to minimize tissue damage.
Orofacial nociceptive measurement in the tongue cancer mouse model
The dolognawmeter is a validated device and assay invented to measure oral function and nociception in mice with oral cancer. 6 In brief, each mouse was placed into a confinement tube with 2 obstructing dowels in series. The mouse voluntarily gnaws through the 2 dowels to escape from confinement within the tube. Each obstructing dowel is connected to a digital timer. When the dowel is severed by the gnawing of the mouse, the timer automatically stops and records the duration of time to sever each of the 2 dowels. To acclimatize the mice and improve consistency in gnawing duration, all mice were trained for 5 sessions in the dolognawmeter. Training involves placing the animals in the device and allowing them to gnaw through the obstructing dowels in exactly the same manner that they do so during the subsequent experimental gnawing trials. A baseline gnaw-time value to sever the second dowel was established for each mouse as the mean of the final 3 training sessions. After baseline gnaw-times were established for each mouse, the mice were inoculated with HSC-3 expressing GFP (n 5
Statistical analysis
Statistical analysis was performed using SigmaPlot for Windows (Version 11.0). Data were analyzed using Student t test, one-way analysis of variance (ANOVA), ANOVA on the ranks, Holm-Sidak, or Dunn test as appropriate. Statistical significance was set at P , 0.05. Results were presented as mean 6 SEM.
Results
The transfection efficiency of luciferase plasmid with mTat/FH in gingival fibroblasts and oral squamous cell carcinoma cells
To clarify differences in transfection of HGF-1 and HSC-3, transfection efficiency was measured by luciferase activity. Plasmid DNA without the vector/DNA was used for control. The luciferase expression in HSC-3 cells was significantly higher (;45-fold) than that in HGF-1 cells (P , 0.001) (Fig. 1). 
The effect of transfection with mTat/FH on the viability of human oral squamous cell carcinoma-3 cells
To investigate the effect of transfection reagents after transfection, cell viability with the mTat/FH/GFP or mTat/FH/OPRM1-GFP complex for transfection in HSC-3 cells was evaluated by MTT assay. There was no significant difference among these groups (P 5 0.072) (Fig. 1B) .
Characterization of transfection parameters in gingival fibroblasts and oral squamous cell carcinoma cells
To characterize transfection parameters in HGF-1 and HSC-3 cells, we first measured gene expressions of caveolin in both cells using quantitative real-time PCR. The gene expression of caveolin in HSC-3 cells was significantly higher (;5-fold) than that in HGF-1 cells (P , 0.001) (Fig. 2A) . In addition, the zeta potentials of both cell types were determined to assess the charge of cell membrane. The zeta potential of HSC-3 cells (29.1 6 2.2 mV) was significantly less negative compared with that of HGF-1 cells (214.8 6 1.9 mV) (P , 0.05) (Fig. 2B) . 
Fluorescence protein expression in oral squamous cell carcinoma cells transfected with a nonviral vector/OPRM1-GFP
To explore the biological role of OPRM1 re-expression on cancer cells, the nonviral vector mTat/FH with plasmid DNA encoding OPRM1 gene tagged with GFP was transfected into HSC-3 in vitro. Green fluorescence protein expression was observed and used as a surrogate for OPRM1 expression subsequent to transfection. Figure 3A shows that GFP expression was observed in oral SCC cells transfected with OPRM1-GFP plasmid. Similarly, GFP expression was observed in HSC-3 cells transfected with GFP control plasmid. No GFP was detected in control nontransfected HSC-3 cells. The transfection of OPRM1-GFP plasmid showed similar expression efficiency to that of the control GFP plasmid (65.5 6 4.9% and 66.6 6 3.5%, respectively; P 5 0.97) (Fig. 3B) .
OPRM1 mRNA and m-opioid receptor expression in gingival fibroblasts and oral squamous cell carcinoma cells stably transfected with OPRM1 plasmid
Quantitative real-time PCR quantification of OPRM1 mRNA expression showed that HSC-3 cells transfected with OPRM1-GFP plasmid had a significantly higher expression (;40-fold) than HSC-3 cells transfected with the control GFP plasmid (P , 0.001) (Fig. 4A) . The expression level of GFP plasmid transfection group was similar to the control nontransfected cells. Furthermore, the results of ELISA showed that MOR expression in OPRM1-GFP plasmid-transfected HSC-3 cells (31.8 6 4.7 pg/10 6 cells) was significantly higher than that in control GFP-transfected cells (3.8 6 0.8 pg/10 6 cells) (P , 0.01). Also, MOR expression in OPRM1-GFP plasmid-transfected HGF-1 cells (4.7 6 0.6 pg/10 6 cells) was significantly higher than that in control GFP-transfected cells (P , 0.05) though it was significantly lower than that in OPRM1-GFP plasmid-transfected HSC-3 cells (P , 0.001, Fig. 4B ). The expression level in GFP-transfected groups was also similar to that in the control nontransfected cells groups.
3.6. Oral squamous cell carcinoma tumors re-expressing m-opioid receptor produced lower levels of mechanical allodynia than control tumors in the paw cancer models Human oral SCC-3 cells that were transfected with either GFP or OPRM1 were inoculated into the right hind paw to create the cancer mouse model. The paw was chosen as a site of oral cancer inoculation because the current gold standard assay to quantify mechanical or thermal hypersensitivity is the paw withdrawal assay. The 2 groups, (1) HSC-3 tumors expressing GFP and (2) HSC-3 tumors expressing OPRM1, had paw volumes that were not significantly different from each other. Average paw volume at baseline for both groups was 0.17 mL. Average paw volumes at PID 17 were 0.29 mL and 0.26 mL, respectively. There was no difference in cellular proliferation, as measured by Ki67, in the HSC-3 tumors expressing GFP or OPRM1 (Fig. 5) . Therefore, re-expressing OPRM1 did not significantly change tumor proliferation. Re-expression of OPRM1 did, however, affect mechanical allodynia. Tumors re-expressing OPRM1 showed a significantly higher mechanical threshold than control tumors expressing GFP. Figure 6A shows that mice with tumors re-expressing OPRM1 had significantly higher mechanical thresholds than the control mice on both PIDs 13 and 17. Mice with tumors expressing OPRM1 had thresholds 32% and 44% below day 0 baseline (group average 5 4.6 g) on PIDs 13 and 17, respectively (Fig. 6B) . Control mice, however, had thresholds 77% and 70% below day 0 baseline (group average 5 4.9 g).
Oral squamous cell carcinoma tumors re-expressing OPRM1 demonstrated lower levels of thermal hyperalgesia than control tumors in the paw cancer model
Using the Hargreaves test 19 as a measure for thermal hyperalgesia, we determined that mice with tumors re-expressing OPRM1 experienced a significantly longer latency period than the control groups. The day 0 baseline latency for the GFP and OPRM1 groups were 4.0 seconds and 4.1 seconds, respectively. Figure 7A shows that mice with tumors re-expressing OPRM1 had significantly longer thermal thresholds than the control mice on both PIDs 13 and 17. The latencies for the GFP group on PIDs 13 and 17 were 40% and 45% below baseline, whereas the latencies for the OPRM1 group were only 21% and 31% below baseline on the same days. OPRM1 re-expression resulted in significantly lower thermal hyperalgesia (Fig. 7B) .
Oral squamous cell carcinoma tumors re-expressing OPRM1 demonstrated less orofacial nociception in the tongue cancer model
Human oral SCC-3 cells that were transfected with either GFP or OPRM1 were inoculated into the tongue to create the tongue cancer mouse model. The OPRM1 exhibited significantly less orofacial nociception, as demonstrated by reduced change in gnaw time relative to baseline as compared with the GFP group at 15 days after inoculation (Fig. 8) .
Mechanical and thermal antinociception are reversed by local naloxone administration
To determine whether the antinociceptive effect that resulted from OPRM1 expression was naloxone-dependent, we tested the effect of local naloxone administration on mechanical and thermal hypersensitivity on PID 19. Five mice in the GFP and OPRM1 groups were used for each type of hypersensitivity test. Figure 9 shows the results after naloxone administration for mechanical and thermal behavioral testing. The absolute values were compared with baseline values on day 0 before cancer inoculation. The mechanical antinociceptive effect present in the OPRM1 group was reversed with naloxone administration and lasted 60 minutes after injection. While the preinjection mechanical threshold in the OPRM1 group was 43% below baseline, the threshold decreased to 75% below baseline 10 minutes after naloxone injection. At 24 hours after injection, the mechanical threshold was again at 43% below baseline. Naloxone did not cause the same significant decrease in mechanical threshold in the GFP group. The thermal antinociceptive effect was also reversed in the OPRM1 group after local naloxone administration to the right hind paw and the effect lasted 60 minutes. The thermal threshold of the OPRM1 group dropped from 33% preinjection to 62% 10 minutes after injection. By 24 hours postinjection, the thermal threshold had increased back to 25% below baseline. Naloxone did not cause a significant decrease in thermal latency in the GFP group. Of note, however, the GFP group had an increase in both mechanical and thermal thresholds immediately after injection, attributable to sedation from isoflurane anesthesia used during drug injection.
3.10. b-endorphin, met-enkephalin, and leu-enkepalin secretion in gingival fibroblasts and oral squamous cell carcinoma cells expressing OPRM1
The mechanical and thermal antinociceptive effects in the OPRM1 groups were reversible by naloxone, suggesting an opioiddependent antinociceptive mechanism. We wanted to determine whether the effect was due to endogenous opioid secretion into the cancer microenvironment. We measured b-endorphin in the supernatant of HSC-3 cells that were stably transfected with OPRM1 plasmid. We also determined the effect of CTOP, a selective MOR antagonist, on b-endorphin secretion. Figure 10 shows that OPRM1-expressing HSC-3 cells (185 6 13 pg/mL) had significantly increased b-endorphin secretion compared with nontransfected cells (69 6 13 pg/mL) and GFP-expressing cells (74 6 13 pg/mL) (one-way ANOVA, Holm-Sidak test, P , 0.001). OPRM1-expressing HSC-3 cells treated with CTOP showed a significant dose-dependent (10 210 to 10 212 M) decrease in b-endorphin secretion (Fig. 10) . In contrast, b-endorphin was not detected from OPRM1-expressing HGF-1 cells. OPRM1-expressing HGF-1 and HSC-3 cells did not have significant met-enkephalin and leuenkepalin secretion compared with nontransfected cells and GFPexpressing cells (data not shown).
Discussion
Using an ex vivo, nonviral, gene transfer method in this study, we demonstrated that re-expression of OPRM1 led to significant attenuation of cancer pain behavior in a cancer mouse model. or GFP plasmid was measured by ELISA. Statistical comparison was analyzed between OPRM1 plasmid and other groups. *P , 0.05, **P , 0.01, and ***P , 0.001. ELISA, enzyme-linked immunosorbent assay; GFP, green fluorescent protein; HGF, human gingival fibroblast; HSC, human oral squamous cell carcinoma; QRT, quantitative reverse transcription.
The magnitude of pain attenuation following transfection with our novel method was similar to that resulting from adenoviral transduction of the OPRM1 gene. 49 There are limitations of the model we used. We used an orthotopic xenograft model which is created by inoculating HSC-3 into immunocompromised mice. The BALB/c Foxn1 nu lack cell-mediated immunity which might impact the pain response. Using naloxone, we demonstrated that the analgesic mechanism of our nonviral method entailed secretion of endogenous opioids into the cancer microenvironment. The stroma is a potential source of b-endorphin in the cancer microenvironment; however, we favor the cancer as the primary source of b-endorphin. In a previous publication, we showed that cancer cells secrete b-endorphin after transduction with OPRM1. We confirmed these findings in this study using nonviral transfection. We also confirmed that nonviral transfection is an effective approach for gene therapy in the treatment of cancer pain. It should be noted that inhalational isoflurane was administered before the injection of naloxone which might explain the antinociceptive effect observed shortly after the administration of naloxone in the control group.
Gene therapy has shown promise in treating chronic pain, but most published preclinical and clinical trials used viral vectors including adenovirus, adeno-associated virus, retrovirus, or herpes simplex virus (HSV). 14, 53 In a recent series of studies, Fink and colleagues delivered an HSV-based vector expressing different pain or analgesic mediators to peripheral sensory neurons. These studies demonstrated a reduction of pain-related responses in rodent models of inflammatory pain, neuropathic pain, and bone cancer-induced pain. The tested mediators included d-opioid agonist peptide enkephalin, 24, 31 IL-10, 59 vascular endothelial growth factor, 3 and tumor necrosis factor a. 16 In addition, the investigators performed a phase-I human clinical trial using the HSV vector encoding enkephalin for the treatment of moderate-to-severe intractable pain caused by head and neck cancer. 8 Viral vectors such as those that employ adenoviruses have proven to be cytotoxic. Nonviral vectors are less toxic and overcome other problems encountered in viral vector-mediated therapy, including elevated immune response, limited DNA-carrying capacity, recombination, and limited stability of gene expression. In this study, we stably expressed OPRM1 using our nonviral vector. The sustained gene expression that we achieved would not have been possible with a viral vector (due to vector cytotoxicity). Our vector, mTat/FH, has low cytotoxicity and high transfection efficiency in vitro. 55 Furthermore, the transfection efficiency (expression ;65% at 2 days after transfection) is higher than the transduction efficiency with an adenoviral vector (;50%). 11 In addition, our in vivo studies using an mTat/FH vector demonstrate long-term transgene expression (;7 months) with little immune response after intramuscular injection of the vectors. 54 Our vector mTat/FH/DNA complex exhibits high expression efficiency because the zeta (electric) potential of the complex is less negatively charged and the particle size of the complex is smaller than the mTat or FH complex. The increased efficiency of nonviral gene transfection is beneficial for patient care because a smaller vector dose is sufficient.
Interestingly, our current study demonstrated that our nonviral vector, mTat/FH, preferentially transfects oral cancer cells without affecting cell viability. To investigate the mechanism by which cancer cells are preferentially transfected, we studied several parameters related to transfection. Because our previous study demonstrated that internalization of mTat/FH vector is mediated by caveolae-mediated endocytic pathway, 55 we measured mRNA expression of caveolin, an integral component of caveolae, in oral cancer cells and in normal fibroblasts. We found that the caveolin gene expression was higher in oral cancer cells than normal fibroblasts. Our findings related to zeta potential in oral cancer cells are similar to findings in cancer cells from other tissues including liver, breast, stomach, and pancreas. Cancers in these other tissues have been found to have more positive electric charge compared with those in normal cells. 29, 35, 58 Surface electric charge of cancer cells seems to be more suitable for transfection compared with that of normal fibroblasts. In addition, in vitro studies demonstrate that several types of cancer cells are softer than their normal tissue counterparts. 13, 25, 26, 43, 45 Cancer cells have proven to be approximately 70% softer than normal cells that line the body cavity. 4 A reduction in membrane tension stimulates endocytosis. 40, 41 Our nonviral approach targets cancer cells while an HSV-based gene transfer technique targets neurons. The cancer cells targeted in our approach induce production of endogenous opioids. Secreted opioids remain in the cancer microenvironment and produce peripheral analgesia. We demonstrated that peripheral analgesia proved to be reversible with local naloxone administration. Most other gene transfection approaches that have been developed for cancer pain target the central nervous system, especially dorsal root ganglion (DRG) and spinal cord. 12, 14 Our rationale for targeting cancer cells rather than neurons is that cancer cells secrete a host of mediators that facilitate cancer-neuron crosstalk; either algesia or analgesia can be generated depending on the mediator. A large body of literature, including previous publications from our laboratory, supports the plausibility of an endogenous opioid approach for pain relief. 2, 5, 9, 28, 36, 39 Because almost all forms of cancer pain are generated at the site of the cancer, therapy targeted to the cancer microenvironment could reverse pain-producing mechanisms at the source and free patients of systemic drug toxicity.
In our nonviral approach, we only transfected cancer cells but the same transfection technique could be used to target neurons for the treatment of pain. Previously published work has demonstrated nonviral transfection in neurons. Plasmid DNAs with liposomes have low immunogenicity, a high level of transgene expression, and high transfection efficiency, 42 including transfection in DRG neurons following intrathecal injection. 51 To increase specificity, nerve growth factor peptides have been used to promote binding of naked DNA complexes to TrkA-positive DRG neurons. 57 A fragment of the tetanus toxin nontoxic subunit has been used to target the tetanus toxin receptor on DRG neurons. 37 We propose that nonviral gene transfection is a potentially effective, long-term treatment modality for cancer pain. We have demonstrated that the cancer microenvironment can be manipulated by selective gene transfer to the cancer through hybrid nonviral gene transfection. Our nonviral approach might be a viable option to treat cancer pain at its source in patients. Our nonviral approach might also be refined to achieve gene transfection in neurons adjacent to the cancer. . Graph shows percent change in mean paw withdrawal threshold from day 0 baseline. Mice in the OPRM1 group have less mechanical allodynia than control mice, but this effect is reversed with naloxone administration. Naloxone reversal brings the threshold of the OPRM1 group to a lower threshold than that of the GFP group. The effect lasts 60 minutes; the OPRM1 group returns to its preinjection baseline by 24 hours. (B) Mice in the OPRM1 group have less thermal hyperalgesia than those in the GFP group, represented by a smaller change from baseline latency. After naloxone administration, however, mice in the OPRM1 group have increased thermal hyperalgesia indicated by a decrease in threshold, whereas the GFP group does not see a similar change. This effect lasts 60 minutes. By 24 hours, mice in the OPRM1 group have returned to their preinjection threshold, which is higher than that of those in the GFP group. *P , 0.05 and **P , 0.01. GFP, green fluorescent protein; HSC, human oral squamous cell carcinoma; PID, postinoculation day. 
